Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    HCV | Open Studies | Interventional Studies | United States, Florida | Adult | Phase 2, 3, 4
Show Display Options
Rank Status Study
1 Recruiting Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
Conditions: HIV-1 Infection;   HCV Infection
Interventions: Drug: E/C/F/TAF;   Drug: F/R/TAF;   Drug: LDV/SOF
Age: 18 Years and older   (Adult, Senior)
2 Recruiting Study of Oral Treatments for Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: sofosbuvir/ledipasvir;   Drug: ombitasvir/paritaprevir/ritonavir;   Drug: elbasvir/grazoprevir;   Drug: Dasabuvir
Age: 18 Years and older   (Adult, Senior)
3 Recruiting Efficacy and Safety of MK-3682B (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)
Conditions: Hepatitis;   Hepatitis C;   Digestive System Diseases;   Flaviviridae Infections;   Hepatitis, Viral, Human;   Liver Diseases;   RNA Virus Infections;   Virus Diseases
Interventions: Drug: MK- 3682B;   Drug: Ribavirin
Age: 18 Years and older   (Adult, Senior)
4 Recruiting Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT);   Drug: Dasabuvir (DSV);   Drug: Ribavirin (RBV)
Age: 18 Years to 70 Years   (Adult, Senior)
5 Recruiting Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency
Condition: HCV Infection
Interventions: Drug: SOF 100 mg;   Drug: SOF 400 mg;   Drug: RBV;   Drug: LDV/SOF
Age: 18 Years and older   (Adult, Senior)
6 Recruiting A Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Patients With Advanced Liver Cancer
Condition: Hepatocellular Carcinoma
Interventions: Biological: Nivolumab;   Drug: Sorafenib;   Drug: Ipilimumab
Age: 18 Years and older   (Adult, Senior)

Indicates status has not been verified in more than two years